Published in Gynecol Endocrinol on March 01, 2006
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74
Sexual differences in the control of energy homeostasis. Front Neuroendocrinol (2009) 1.50
Early menopause, association with tobacco smoking, coffee consumption and other lifestyle factors: a cross-sectional study. BMC Public Health (2007) 1.00
Relationships between body fat distribution, epicardial fat and obstructive sleep apnea in obese patients with and without metabolic syndrome. PLoS One (2012) 0.97
Significant associations of age, menopausal status and lifestyle factors with visceral adiposity in African-American and European-American women. Ann Hum Biol (2010) 0.91
Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women. PLoS One (2009) 0.90
Effects of chronic swimming training and oestrogen therapy on coronary vascular reactivity and expression of antioxidant enzymes in ovariectomized rats. PLoS One (2013) 0.87
Sex and sex steroids: impact on the kinetics of fatty acids underlying body shape. Horm Mol Biol Clin Investig (2014) 0.77
Do diabetes and depressed mood affect associations between obesity and quality of life in postmenopause? Results of the KORA-F3 Augsburg population study. Health Qual Life Outcomes (2011) 0.77
The effects of Sutaehwan-Gami on menopausal symptoms induced by ovariectomy in rats. BMC Complement Altern Med (2012) 0.76
Body Image in Adult Women: Moving Beyond the Younger Years. Adv Eat Disord (2015) 0.75
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. J Cardiovasc Med (Hagerstown) (2009) 1.44
IMS updated recommendations on postmenopausal hormone therapy. Climacteric (2007) 1.20
Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J (2007) 1.07
EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas (2010) 0.97
EMAS position statement: Vitamin D and postmenopausal health. Maturitas (2011) 0.92
EMAS position statement: Managing women with premature ovarian failure. Maturitas (2010) 0.86
EMAS position statement: managing obese postmenopausal women. Maturitas (2010) 0.85
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril (2010) 0.84
EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas (2011) 0.84
Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas (2005) 0.79
Hormonal influence on the central nervous system. Maturitas (2002) 0.79
Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas (2002) 0.79
Hormone therapy. Menopause (2003) 0.78
EMAS position statement: managing the menopause in women with epilepsy. Maturitas (2010) 0.78
Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception (2007) 0.78
[Management of cardiovascular risk in the peri-menopausal woman--a consensus statement of European cardiologists and gynaecologists]. Kardiol Pol (2007) 0.77
The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women. Gynecol Endocrinol (2007) 0.77
EMAS position statement: Bone densitometry screening for osteoporosis. Maturitas (2010) 0.77
EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas (2010) 0.77
Clinical relevance of the HERS trial. Lancet (2002) 0.76
Vasomotor symptoms and negative affect: time to act. Menopause (2011) 0.75
Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. Gynecol Endocrinol (2007) 0.75
From the challenge to the reassessment of the Women's Health Initiative: a personal initiative for women's health. Gynecol Endocrinol (2006) 0.75
Recommendations on the management of fragility fracture risk in women younger than 70 years. Gynecol Endocrinol (2012) 0.75
EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis. Maturitas (2011) 0.75
The Xmas present for women's health: a strike to osteoporosis prevention. Maturitas (2004) 0.75
Risk identification of osteoporosis in postmenopausal women by a simple algorithm based on ultrasound densitometry and body mass index. J Clin Densitom (2008) 0.75
Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric (2004) 0.75
The osteoporosis dilemma. Gynecol Endocrinol (2004) 0.75
"Controversial issues in climacteric medicine" series 3rd Pisa workshop "HRT in climacteric and aging brain". Pisa, Italy, 15-18 March 2003. Maturitas (2003) 0.75
The sound of an International anti-HRT herald. Maturitas (2003) 0.75